Recently, Howard et al. [142] demonstrated that cardiac glycosides showed a synergistic anticancer effect on triple-negative breast cancer cells MDA-MB-231 by inhibiting the expression of eukaryotic translation initiation factor 4A1 (EIF4A1) in a C-Myc dependent mechanism. Here, EIF4A1 is linked to triple-negative breast carcinoma.